Linda S. Wicker

Linda S. Wicker

Auto-generated profile, based on publicly available information

Linda S. Wicker

University of Oxford

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2007 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JYJun Yamanouchi
Jun Yamanouchi
DRDan Rainbow
Dan Rainbow
PSPau Serra
Pau Serra
SHSarah Howlett
Sarah Howlett
KHKara Hunter
Kara Hunter
Pere SantamariaPere Santamaria
Pere Santamaria

14 June 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
CRCatherine C. Robertson
Catherine C. Robertson
JIJamie R. J. Inshaw
Jamie R. J. Inshaw
SOSuna Onengut-Gumuscu
Suna Onengut-Gumuscu
WCWei-Min Chen
Wei-Min Chen
DCDavid Flores Santa Cruz
David Flores Santa Cruz
SRStephen S. Rich
Stephen S. Rich

23 August 2009 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
Calliope DendrouCalliope Dendrou
Calliope Dendrou
VPVincent Plagnol
Vincent Plagnol
EFErik Fung
Erik Fung
JYJennie H M Yang
Jennie H M Yang
KDKate Downes
Kate Downes
LWLinda S Wicker
Linda S Wicker

1 December 2018 in Journal of Autoimmunity
Verified
Journal Article
Open access
LPLaurence B. Peterson
Laurence B. Peterson
CBCharles J.M. Bell
Charles J.M. Bell
SHSarah K. Howlett
Sarah K. Howlett
MPMarcin L. Pekalski
Marcin L. Pekalski
KBKevin Brady
Kevin Brady
LWLinda S. Wicker
Linda S. Wicker
Susceptibility to multiple autoimmune diseases is associated with common gene polymorphisms influencing IL-2 signaling and Treg function, making Treg-specific expansion by IL-2 a compelling therapeutic approach to treatment. As an in vivo IL-2 half-life enhancer we used a non-targeted, effector-function-silent human IgG1 as a fusion protein. An IL-2 mutein (N88D) with reduced binding to the intermediate affinity IL-2Rβγ receptor was engineered with a stoichiometry of two IL-2N88D molecules per IgG, i.e. IgG-(IL-2N88D)2. The reduced affinity of IgG-(IL-2N88D)2 for the IL-2Rβγ receptor resulted in a Treg-selective molecule in human whole blood pSTAT5 assays. Treatment of cynomolgus monkeys with single low doses of IgG-(IL-2N88D)2 induced sustained preferential activation of Tregs accompanied by a corresponding 10-14-fold increase in CD4+ and CD8+ CD25+FOXP3+ Tregs; conditions that had no effect on CD4+ or CD8+ memory effector T cells. The expanded cynomolgus Tregs had demethylated FOXP3 and CTLA4 epigenetic signatures characteristic of functionally suppressive cells. Humanized mice had similar selective in vivo responses; IgG-(IL-2N88D)2 increased Tregs while wild-type IgG-IL-2 increased NK cells in addition to Tregs. The expanded human Tregs had demethylated FOXP3 and CTLA4 signatures and were immunosuppressive. These results describe a next-generation immunotherapy using a long-lived and Treg-selective IL-2 that activates and expands functional Tregsin vivo. Patients should benefit from restored immune homeostasis in a personalized fashion to the extent that their autoimmune disease condition dictates opening up the possibility for remissions and cures.

1 January 2005 in Journal of Autoimmunity
Verified
Journal Article
Closed access
LWLinda S. Wicker
Linda S. Wicker
JCJan Clark
Jan Clark
HFHeather I. Fraser
Heather I. Fraser
VGValerie E.S. Garner
Valerie E.S. Garner
AGAndrea Gonzalez-Munoz
Andrea Gonzalez-Munoz
LPLaurence B. Peterson
Laurence B. Peterson

1 January 2015 in Journal of Autoimmunity
Verified
Journal Article
Open access
CBCharles J.M. Bell
Charles J.M. Bell
YSYongliang Sun
Yongliang Sun
UNUrszula M. Nowak
Urszula M. Nowak
JCJan Clark
Jan Clark
SHSarah Howlett
Sarah Howlett
LPLaurence B. Peterson
Laurence B. Peterson
Regulatory T cells (Tregs) expressing FOXP3 are essential for the maintenance of self-tolerance and are deficient in many common autoimmune diseases. Immune tolerance is maintained in part by IL-2 and deficiencies in the IL-2 pathway cause reduced Treg function and an increased risk of autoimmunity. Recent studies expanding Tregs in vivo with low-dose IL-2 achieved major clinical successes highlighting the potential to optimize this pleiotropic cytokine for inflammatory and autoimmune disease indications. Here we compare the clinically approved IL-2 molecule, Proleukin, with two engineered IL-2 molecules with long half-lives owing to their fusion in monovalent and bivalent stoichiometry to a non-FcRγ binding human IgG1. Using nonhuman primates, we demonstrate that single ultra-low doses of IL-2 fusion proteins induce a prolonged state of in vivo activation that increases Tregs for an extended period of time similar to multiple-dose Proleukin. One of the common pleiotropic effects of high dose IL-2 treatment, eosinophilia, is eliminated at doses of the IL-2 fusion proteins that greatly expand Tregs. The long half-lives of the IL-2 fusion proteins facilitated a detailed characterization of an IL-2 dose response driving Treg expansion that correlates with increasingly sustained, suprathreshold pSTAT5a induction and subsequent sustained increases in the expression of CD25, FOXP3 and Ki-67 with retention of Treg-specific epigenetic signatures at FOXP3 and CTLA4.